The investigators enrolled 225 adults and divided them into three equal groups: Type 2 diabetes mellitus (T2DM) patients with diabetic neuropathy (DN), T2DM patients without neuropathy, and healthy non‑diabetic controls. Participants ranged from 25 to 70 years and were recruited from two hospitals in Bangladesh between June and December 2025. The study excluded pregnant women and individuals with alternative causes of peripheral neuropathy, such as vitamin B12 deficiency, hypothyroidism, chronic alcohol use, prior neurotoxic chemotherapy, chronic kidney disease, or other neurologic disorders. Clinical evaluation for DN combined bedside testing — 10 g monofilament for pressure, a 128 Hz tuning fork for vibration, pinprick for nociception — with the Michigan Neuropathy Screening Instrument (MNSI). The research team defined neuropathy as abnormal clinical findings and/or an MNSI score ≥2.5. Participants were predominantly of Bengali ethnic origin; investigators noted limited information on finer-scale ancestry markers and considered the risk of major population stratification low but not excluded.
Genomic DNA extraction and PCR-based genotyping targeted IL6 rs1800796 (−572 G/C) and IL10 rs1800896 (−1082 G/A). Serum cytokine concentrations were measured using enzyme-linked immunosorbent assay (ELISA). The article reported groupwise genotype frequencies and correlated genotype classes with circulating cytokine levels, but did not provide additional mechanistic or functional assays beyond the genotyping and ELISA measurements. Statistical comparisons included unadjusted odds ratios for genotype associations and multivariable adjustments to test independent effects on DN risk.
Data indicated that serum IL-6 levels were significantly higher in the DN group compared with both diabetic participants without neuropathy and healthy controls (p < 0.0001). The highest mean concentrations appeared among individuals carrying the IL6 rs1800796 CC genotype. The study team reported that serum IL-6 showed discriminatory capacity in distinguishing patients with DN from the other study groups, although exact performance metrics (for example, area under the curve values) were presented in the full manuscript figures and tables rather than summarized in the abstract. By contrast, serum IL-10 levels did not differ significantly across groups (p = 0.0948), suggesting no clear group-level change for this anti‑inflammatory cytokine within this cohort.
In unadjusted analyses, the IL6 rs1800796 CC genotype was associated with increased odds of DN versus healthy controls; the IL10 rs1800896 GG genotype also showed an unadjusted association with DN. These genotype associations were reported with corresponding odds ratios and confidence intervals in the manuscript. When models incorporated multivariable adjustment for potential confounders, neither the IL6 nor the IL10 genotype remained independently associated with DN. Investigators therefore cautioned that observed genotype associations in the unadjusted comparisons may reflect confounding or limited sample power rather than robust genetic effects.
The authors examined combined genotype profiles across the two loci and reported several nominal associations with DN status; they characterized these findings as exploratory. Serum IL-6 emerged as the more promising single biomarker in this dataset, whereas IL-10 offered limited discriminatory performance. The paper did not report any functional assays linking promoter polymorphisms to transcriptional activity within this cohort, so mechanistic inferences about how rs1800796 or rs1800896 would alter cytokine production were not provided beyond genotype–phenotype correlations.
The authors listed several constraints that temper interpretation. This was a relatively small, hospital‑based case‑control study carried out in a single-country population predominantly of Bengali ethnicity; therefore, sample size and population homogeneity limit generalizability. The cross-sectional, case-control design precludes causal inference and temporal assessment of cytokine changes relative to neuropathy onset. Although unadjusted genotype associations were observed, multivariable models attenuated those signals, indicating potential confounding or limited statistical power. The investigators stated that their findings support further study of serum IL-6 as a candidate biomarker for diabetic neuropathy, but emphasized that larger prospective studies with independent external validation are required before any clinical application can be considered. The manuscript did not report additional mechanistic work, and no regulatory milestones or biomarker qualification steps were documented in the article.